Startups
Oxalo Therapeutics is developing a novel drug to prevent recurrent kidney stones. Spun out from the University of Chicago, we use breakthrough discoveries from microbiome research to finally address an underlying cause of kidney stones. Every year kidney stones cause 1.3M+ ER visits and $10+ billion of healthcare costs. Most dangerously, they have a recurrence rate of ~70%. By focusing on prevention, we can end the debilitating pain and tremendous economic burden of this chronic disease.
Overview
Employees
11-50
Founded date
2018
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 1, 2018 | Here’s the Chicago Tech Companies That Raised Money in September | This is our round up of Chicago tech and startup companies that received venture capital investments during the month of September. If we missed one, let us know at [email protected]. To get funding updates in your inbox each day, sign u... |
| Sep 24, 2018 | UChicago Biotech Startup Gets $2.3M From NIH, Makes MassChallenge Finals | Chicago biotech company Oxalo Therapeutics, which is developing a drug to treat and prevent kidney stones, has made it to the final round of a high-profile startup accelerator competition while also picking up some new funding to grow. Oxal... |
| Sep 19, 2018 | MassChallenge Names Top 2018 Startups in Boston and Rhode Island | September 19, 2018, BOSTON – MassChallenge, a global network of zero-equity startup accelerators, today announced the top startups from its 2018 Boston and Rhode Island programs, which together accelerated more than 150 startups across indu... |
| May 23, 2018 | Announcing the 2018 MassChallenge Boston Cohort | We’re thrilled to introduce this year’s MassChallenge Boston cohort, which was selected from more than 1,600 applications from around the world, including 11 countries and 16 U.S. states. Representing the top 8% of all applicants, these 128... |
Reviews 0
FAQ about Oxalo Therapeutics
When was Oxalo Therapeutics founded?
Oxalo Therapeutics was founded in 2018.
What has the press written about Oxalo Therapeutics?
Parsers VC has collected 5 articles mentioning Oxalo Therapeutics, among them “Here’s the Chicago Tech Companies That Raised Money in September” (Oct 1, 2018) and “UChicago Biotech Startup Gets $2.3M From NIH, Makes MassChallenge Finals” (Sep 24, 2018).
Is Oxalo Therapeutics still active?
Yes, Oxalo Therapeutics is active; its latest activity on Parsers VC dates from Oct 17, 2018.